| abstract |
The invention relates to 6- (1-methyl-1H-pyrazol-4-yl) -2- {3- [5- (2-morpholin-4-yl-ethoxy) -pyrimidin-2-yl] benzyl} -2H-pyridazin-3 dihydrogen phosphate -one, its solvates and crystalline modifications. The invention also relates to methods for producing these crystalline modifications, as well as their use in the treatment and / or prophylaxis of physiological or pathophysiological conditions caused, mediated and / or propagated by inhibition, regulation and / or modulation of transduction of kinase signal, in particular tyrosine kinase inhibition, for example pathophysiological conditions such as cancer. |